NCT01534637 - Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

August 31, 2012

Conditions

Extrahepatic Bile Duct CancerNauseaVomitingStage II Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic Cancer

Interventions

DRUG

aprepitant

Given PO

DRUG

gemcitabine hydrochloride

Given IV

DRUG

capecitabine

Given PO

DRUG

fluorouracil

Given IV

PROCEDURE

radiation therapy

Undergo radiation therapy

OTHER

questionnaire administration

Ancillary studies

PROCEDURE

quality-of-life assessment

Ancillary studies

PROCEDURE

nausea and vomiting therapy

Receive aprepitant

PROCEDURE

management of therapy complications

Receive aprepitant

Trial Locations (1)

27157

Wake Forest University Health Sciences, Winston-Salem

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Wake Forest University Health Sciences

OTHER